S
Singulex
Life Science Products and Cardiovascular Monitoring
About Singulex
Singulex is a commercial stage, privately held company specializing in Next Generation Immunodiagnostics (NGI). The company leverages its proprietary Single Molecule Counting technology to provide unprecedented ultra-sensitivity in the precision measurement of biomarkers. This technology enables reliable and accurate health status assessments, which are crucial for physicians and patients in making informed healthcare decisions. Singulex primarily serves the medical and healthcare sectors, focusing on improving health outcomes and reducing healthcare costs without compromising the quality of care. The company's business model revolves around the development and commercialization of diagnostic systems and tests, such as the Sgx system, which is designed to offer high sensitivity and specificity in detecting biomarkers. Singulex generates revenue through the sale of its diagnostic products and services to healthcare providers and institutions. The company operates in the competitive immunodiagnostics market, where innovation and precision are key differentiators.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2003
- Headquarters
- Alameda, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 59.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Testing, Verification, Risk Management, Biotechnology, Cardiology and cardiovascular, Patient Care, Spinout, Biotech and Pharma, medical testing, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Apr 2017 | $50M | — | Perceptive Advisors · Silicon Valley Bank · Oxford Finance | — |
| LATE VCOther financing | Jun 2016 | $50M | $200M | Grifols · Silicon Valley Bank · JIF Capital | — |
Growth signals
Latest recorded traffic for Singulex is 2.6K monthly website visits, up 100% over the last three months. Singulex's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later9 investors entered at this stage
Advantage Capital
OrbiMed
JAFCO
Prolog Ventures
JIF Capital
Silicon Valley Bank
Oxford Finance
Perceptive Advisors
Grifols
Other known investors1 additional known investor
University of California, Berkeley
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Singulex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Singulex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.